Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of E2609 in Hepatic Impairment
NCT02859207Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of elenbecestat in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve (0-t) and 1 more. Started Aug 2016; status: completed.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02859207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859207.